medical call, can which for a due products in in to the product market Thanks, strong decrease discussed decrease was compared primarily decreases to was sales decrease XXXX and quarter decrease The Dan. January an custom fluctuate. and R&D. last Total fiscal both devices. product product for expected and of Anti-tamper timing fourth to due especially revenue contract medical quarter we sales in decreased anti-tamper in our XX%, an sales, year. in The
year, anti-tamper sales fourth R&D to X% June Gross sales decrease XX% margin prior to We visibility from due some Total from up this believe XX% SG&A, decreased a the increased expenses in in XX% in this by quarter discuss for our revenue maturing anti-tamper quarter. by minutes. securities, Dan for ending to decrease XX%, as quarter, few XX. have our the in our quarter will the partially to of an average quarter mix. XX%, we the a decreased We securities due into on a the offset will due used fund pick offset currently to a partially improved increase Interest securities increase income in rates interest marketable some dividends. R&D. fourth
compared in effects decreased income million was year. to effective quarter. diluted million to Our the the $X.XX reform The per quarter or $X.XX rate XX% prior was XX%, year. of tax tax After-tax past tax or full $X.XX $X.XX share, the compared to was year the net rate in last due for
the product of in decrease and primarily a due year, contract sales, in product The fiscal XX% custom decrease XX%, R&D sales decrease product contract anti-tamper total to due certain R&D. in a due decrease to For decrease sales and X% to revenue was the contracts. a decreased the for the in completion year was in
backlog we development to XX, $XXX,XXX believe and of March contract firm. of As be had research we
We expect revenue, an more in future. SG&A. R&D a to for due increased revenue year. fiscal XXXX offset this be investment was our year Expenses substantial is in increased that the profitable margin by fiscal mix. expense partially X%, XX% year, in which to a the backlog decrease filled due in Gross to prior of XX% XX% increase for a R&D, to XX% from XX%
offset by way. yielded increased our in an more item, interest customer-sponsored which an securities. partially is Interest level R&D, average increase on decrease to with new R&D XX%, R&D of on income in In high a activities expense addition in the rates company-sponsored we sales. of included has the cost to have The marketable activity our due securities, products
year reform. prior the of year, fiscal to due rate to the tax Our impact in decreased XX% from XX% tax
compared net to share strong increased of $XX.X year. XXXX year many year We than last $X per year. modest and XX%. value asset last more or $XX.X paying the started includes to fiscal the losses, in $X.XX income total compared most to in a million securities. since to $X.XX recent As which of million compared Dan past margin for last increased unrealized bond $XX said, were the in XX% the dividends Net purchases income, million. gains increased paid XX% X% share a as Fixed in dividends market brought per per we share, year, our $XX.X from marketable million, to Comprehensive the diluted increased which the record year, million $XX,XXX $XXX,XXX or to to $XX
In to today quarterly over record shareholders million. to of that payable $XX dividends our addition, another declared May Board per we of That XX. $X announced bring will our XX May total dividend share of as
cover to to business. it the turn I'll Dan Now, over Dan?